At €39.20, Is It Time To Put CompuGroup Medical SE & Co. KGaA (ETR:COP) On Your Watch List?

CompuGroup Medical SE & Co. KGaA (ETR:COP), is not the largest company out there, but it saw significant share price movement during recent months on the XTRA, rising to highs of €52.90 and falling to the lows of €36.52. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether CompuGroup Medical SE KGaA's current trading price of €39.20 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at CompuGroup Medical SE KGaA’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for CompuGroup Medical SE KGaA

Is CompuGroup Medical SE KGaA Still Cheap?

According to my price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that CompuGroup Medical SE KGaA’s ratio of 28.8x is trading in-line with its industry peers’ ratio, which means if you buy CompuGroup Medical SE KGaA today, you’d be paying a relatively sensible price for it. Although, there may be an opportunity to buy in the future. This is because CompuGroup Medical SE KGaA’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What kind of growth will CompuGroup Medical SE KGaA generate?

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 79% over the next couple of years, the future seems bright for CompuGroup Medical SE KGaA. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? COP’s optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at COP? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio?

Are you a potential investor? If you’ve been keeping tabs on COP, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for COP, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

So while earnings quality is important, it's equally important to consider the risks facing CompuGroup Medical SE KGaA at this point in time. You'd be interested to know, that we found 1 warning sign for CompuGroup Medical SE KGaA and you'll want to know about this.

If you are no longer interested in CompuGroup Medical SE KGaA, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.